Author: Aditya Pareek | EQMint | Market News
The Corona Remedies IPO opened for subscription today, creating a significant buzz across the primary market. The pharmaceutical company, known for its strong presence in branded formulations, is one of the most closely watched healthcare listings of the year. From GMP trends to investor demand and valuation analysis, here is the complete breakdown of Day 1 activity — along with an informed view on whether investors should consider subscribing.
IPO Issue Details
Corona Remedies’ maiden public issue is entirely an offer for sale by existing shareholders, meaning no fresh funds are raised for business expansion. The issue size is substantial, highlighting the confidence of the promoters and early investors in the company’s equity value.
Key highlights of the issue structure:
- Offer Type: 100% Offer for Sale (OFS)
- Price Band: ₹1,008 to ₹1,062 per share
- Lot Size: 14 shares and multiples thereafter
- Listing: BSE and NSE
- Investor Allocation: QIB 50%, Retail 35%, NII 15%
Retail investors need around ₹15,000 to make the minimum application at the upper band, positioning the issue well within the reach of small and medium retail participants.
Day 1 Subscription Status
On Day 1, the IPO received steady interest from investors, though full momentum is expected to build over Days 2 and 3, especially from institutional investors. The pattern is similar to many recent mainboard IPOs where subscription typically accelerates closer to closing.
Provisional Day 1 booking snapshot:
- Retail Investors (RII): Moderate interest, below full subscription
- High Net Worth (NII/sNII): Steady participation
- Institutional Investors (QIB): Expected to contribute meaningfully later
- Total Subscription: Modest but building, indicating healthy confidence
Retail subscription, though not skyrocketing on Day 1, reflects constructive sentiment backed by the company’s growth profile.
Grey Market Premium (GMP)
The GMP (Grey Market Premium) has remained positive since the IPO price range was announced. On Day 1, grey-market signals suggested a potential listing gain over the upper band. Though GMP is not an official indicator and should never be the sole investment basis, it does reflect real-time investor sentiment.
Many traders view Corona Remedies’ GMP as encouraging, showing market appetite and expectations of sectoral resilience in healthcare and branded formulations.
Company Background and Business Strengths
Corona Remedies has built a strong reputation in the Indian pharmaceutical sector, especially in branded formulations. The company’s product portfolio spans multiple therapy areas including:
- Cardio metabolic
- Gastrointestinal
- Vitamins and nutrition
- Respiratory
- Pain management
- Women’s health
- Dermatology
Its diverse branded portfolio helps reduce dependency on any single segment and positions the company well against sector shifts. Strong engagement with doctors, an expansive field distribution network, and manufacturing strength contribute to stable revenue traction.
Financial Overview
Corona Remedies has shown healthy financial performance over recent years. Revenues have grown consistently, supported by higher sales volumes and branded presence. Profitability has improved as well, reflecting efficiency and market strength.
Key financial strengths include:
- Growth in revenue and operating margins
- Strong Return on Net Worth (RoNW)
- Healthy earnings visibility
- Competitive performance against peers in the domestic pharma space
The valuation, while not cheap, aligns with premium peers in the branded pharma segment — implying that the market views Corona Remedies as a quality asset.
Industry Positioning and Market Opportunity
The Indian pharmaceutical market continues to expand due to increasing healthcare demand, lifestyle-driven chronic conditions, broader drug accessibility, and rising incomes. Corona Remedies operates in therapy areas that benefit from sustained prescription demand rather than one-time consumption.
This business model supports:
- Predictable recurring revenue
- Higher brand stickiness among doctors
- Better margin opportunities
Its strong presence in chronic therapies is a long-term competitive advantage.
Key Dates to Track
- Issue Opens: 8 December
- Issue Closes: 10 December
- Basis of Allotment: 11 December
- Refunds: 12 December
- Demat Credit: 12 December
- Expected Listing: 15 December
Investors must ensure timely UPI mandate approval before the closing day.
Pros and Cons of the IPO
Strengths
- Diversified branded portfolio
- Steady revenue and profit growth
- Strong domestic market presence
- Attractive industry opportunity
- Healthy grey-market sentiment
Risks
- Entirely OFS — no fresh capital coming into business
- Valuation on the premium side
- Sector exposed to regulatory and price control frameworks
- Domestic concentration increases sensitivity to domestic policy shifts
Should You Subscribe?
The Day 1 response, the company’s financial record, and sustained market sentiment indicate growing confidence in the IPO. While valuation is on the higher side, the firm’s fundamentals support its pricing. The listing outlook appears constructive based on current sentiment indicators.
Verdict:
- Short-term investors looking for listing gains: Attractive, though subject to market conditions.
- Medium to long-term investors: Reasonable opportunity for those comfortable with premium valuations.
- Risk-averse investors: May prefer to track listing and allocate post-debut.
For more such information visit EQMint.
Disclaimer: This article is based on information available from public sources. It has not been reported by EQMint journalists. EQMint has compiled and presented the content for informational purposes only and does not guarantee its accuracy or completeness. Readers are advised to verify details independently before relying on them.
